View : 101 Download: 0

Natural History of Gastric Cancer: Observational Study of Gastric Cancer Patients Not Treated During Follow-Up

Title
Natural History of Gastric Cancer: Observational Study of Gastric Cancer Patients Not Treated During Follow-Up
Authors
Oh S.-Y.Lee J.-H.Lee H.-J.Kim T.H.Huh Y.-J.Ahn H.-S.Suh Y.-S.Kong S.-H.Kim G.H.Ahn S.J.Kim S.H.Choi Y.Yang H.-K.
Ewha Authors
허연주
Issue Date
2019
Journal Title
Annals of Surgical Oncology
ISSN
1068-9265JCR Link
Citation
Annals of Surgical Oncology vol. 26, no. 9, pp. 2905 - 2911
Keywords
Doubling timeGastric cancerNatural historyProgressionSurvival benefit
Publisher
Springer New York LLC
Indexed
SCI; SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Background: Understanding the natural progression of untreated gastric cancer is critical for determining the disease prognosis as well as treatment options and timing. The aim of this study is to analyze the natural history of gastric cancer. Patients and Methods: We included patients with gastric cancer who had not received any treatment and were staged using endoscopy/endoscopic ultrasonography and computed tomography on at least two follow-up visits during intervals of nontreatment. Tumor volumes were also measured in addition to the staging. Survival of each stage at diagnosis was also analyzed. Results: A total of 101 patients were included. The mean follow-up period was 35.1 ± 34.4 months. The gastric cancer doubling time was 11.8 months for T1 and 6.2 months for T4. The progression time from early gastric cancer to advanced gastric cancer was 34 months. It decreased as the stages advanced: from 34 months between tumor-nodes-metastasis stage I and II to 1.8 months between stage III and IV. No variable was identified as a risk factor for cancer progression. The 5-year survival rates of untreated patients were 46.2% in stage I and 0% in stage II, stage III, and stage IV. Conclusions: The progression and doubling times of gastric cancer shorten as the stages advance. Objective data reported in this study can be a critical factor in determining treatment timing and screening interval. © 2019, Society of Surgical Oncology.
DOI
10.1245/s10434-019-07455-z
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE